<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096275</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCHCSTAR-006</org_study_id>
    <nct_id>NCT03096275</nct_id>
  </id_info>
  <brief_title>Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis</brief_title>
  <acronym>CommittedTA</acronym>
  <official_title>Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese SLE Treatment And Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese SLE Treatment And Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Takayasu's arteritis(TAK) is a rare systemic vasculitis which can cause ischemia or
      inflammation of the involved organs and increase the overall mortality rate.The traditional
      treatment of TAK is primarily empirical. The most commonly used drugs for treating active TAK
      are glucocorticosteroids(GC) and immunosuppressants. However, the genital toxicity of CYC has
      limited its long term use. In a pilot study carried out by the principal investigator of this
      study has shown that mycophenolate mofetil(MMF) combined with MTX is effective and with few
      adverse effects. The purpose of this prospective open-label study is to compare the efficacy
      and safety of GC+MMF+MTX with GC+CYC followed by GC+AZA for the treatment of active TAK. 150
      patients with active TAK will be recruited and randomized in a 2:1 ratio to GC+MMF+MTX group
      and C+CYC and AZA group. Patients were followed for 52 weeks for efficacy and safety
      assessment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Takayasu's arteritis(TAK) is a rare systemic vasculitis which mainly involves aorta and its
      major branches. However,it is more prevalent in countries and areas along the silk road.Young
      women at child-bearing age is the most prevalent population.It can cause ischemia or
      inflammation of the involved organs and increase the overall mortality rate.Although it may
      be lethal in some patients,it is not well studied due to the rareness of the disease.The
      traditional treatment of TAK is primarily empirical. The most commonly used drugs for
      treating active TAK are glucocorticosteroids(GC) and immunosuppressants including
      cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc. However,no of these drugs
      have been well studied. In addition, the genital toxicity of CYC, the first line medication
      for active TAK, has become the major limitation for its long term use for a chronic disease
      like TAK. Therefore, new immunosuppressants with less toxicity,especially with much less
      genital toxicity and low malignancy risk is essentially necessary. In a pilot study carried
      out by the principal investigator of this study has shown that mycophenolate mofetil(MMF)
      combined with MTX is effective and with few adverse effects. The purpose of this prospective
      open-label study is to compare the efficacy and safety of GC+MMF+MTX with GC+CYC followed by
      GC+AZA for the treatment of active TAK. 150 patients with active TAK will be recruited and
      randomized in a 2:1 ratio to GC+MMF+MTX group and C+CYC and AZA group. Patients were followed
      for 52 weeks to assess the efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were randomly assigned to two treatment arms and were treated for 12 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with complete remission</measure>
    <time_frame>52 weeks</time_frame>
    <description>The proportion of patients who reached the pre-defined criteria of complete remission in both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with partial remission</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of patients who reached the pre-defined partial remission criteria of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of MMF combined with MTX</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of adverse events in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of patients with complications in both treatment group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Takayasu Arteritis</condition>
  <arm_group>
    <arm_group_label>MMF+MTX+Glucocorticoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYC/AZA+Glucocoticoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
    <description>Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil</description>
    <arm_group_label>MMF+MTX+Glucocorticoids</arm_group_label>
    <other_name>Guangwei</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYC</intervention_name>
    <description>Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine</description>
    <arm_group_label>CYC/AZA+Glucocoticoids</arm_group_label>
    <other_name>huanlinxianan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered</description>
    <arm_group_label>MMF+MTX+Glucocorticoids</arm_group_label>
    <arm_group_label>CYC/AZA+Glucocoticoids</arm_group_label>
    <other_name>qiangdisong</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF</description>
    <arm_group_label>MMF+MTX+Glucocorticoids</arm_group_label>
    <other_name>jiaandieling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZA</intervention_name>
    <description>Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA</description>
    <arm_group_label>CYC/AZA+Glucocoticoids</arm_group_label>
    <other_name>liuzuopiaoling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients older than 18 years-old either sex

          2. Patients with signed informed consent

          3. Fulfill the 1990 ACR Classification Criteria for TAK

          4. Patients with active disease according to GACTA criteria

        Exclusion Criteria:

          1. Prior adverse events when treated with MTX that resulted in dose reduction or
             discontinuation;

          2. Prior treatment with MMF but failed response to MMF;

          3. Prior treatment with CYC but failed response to CYC;

          4. Renal dysfunction, defined as the estimated GFR &lt;80% or serum creatinine level higher
             than 1.5 times of upper normal limit;

          5. Severe liver function damage defined by serum ALT or AST higher than 2 times of the
             upper normal limits;

          6. Uncontrolled diabetes melitus;

          7. Uncontrolled heart failure at baseline;

          8. Active infection including tuberculosis , hepatitis B virus, hepatitis C virus, HIV or
             bacterial or fungal infection;

          9. Active upper GI bleeding in the past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinping Tian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Li, MD</last_name>
    <phone>86-10-69158795</phone>
    <email>lijing_pumch2004@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ai Xu, RN</last_name>
    <phone>86-13717958936</phone>
    <email>1989xuai@sina.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebei Provincial Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fengxiao Zhang, MD</last_name>
      <phone>13722879168</phone>
      <email>fengxiao.zhang@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wei Lin, MD</last_name>
      <phone>17736909239</phone>
      <email>linwei272@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Huhehaote</city>
        <state>Inner Mongolia</state>
        <zip>010050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongbin Li, MD</last_name>
      <phone>13948536552</phone>
      <email>hongbin.li@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ning Tie, MD</last_name>
      <phone>13948610720</phone>
      <email>tieting@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenbiao Wu, MD</last_name>
      <phone>13700235112</phone>
      <email>ping.zhu@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Weitong Chen, MD</last_name>
      <phone>15771943030</phone>
      <email>chenweitong0818@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Zheng, MD</last_name>
      <phone>13911170090</phone>
      <email>yi.zheng@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yongfeng Zhang, MD</last_name>
      <phone>13671239495</phone>
      <email>zyf760116@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinping Tian, MD</last_name>
      <phone>86-13691165939</phone>
      <email>tianxp6@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shi Rong, MD</last_name>
      <phone>86-13601248311</phone>
      <email>rongshipumch@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>XInping Tian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoxia Li, MD</last_name>
      <phone>13501164945</phone>
      <email>xiaoxia.li@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yi Zhao, MD</last_name>
      <phone>13811038669</phone>
      <email>zhaoyi_peking@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>General Hospital of Tianjing Medical University</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Wei, MD</last_name>
      <phone>13920182411</phone>
      <email>wei.wei@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Na Zhang, MD</last_name>
      <phone>13820489562</phone>
      <email>lunazhang22@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug;33(8):1129-34.</citation>
    <PMID>1975175</PMID>
  </reference>
  <results_reference>
    <citation>Goel R, Danda D, Mathew J, Edwin N. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol. 2010 Mar;29(3):329-32. doi: 10.1007/s10067-009-1333-6.</citation>
    <PMID>20054700</PMID>
  </results_reference>
  <results_reference>
    <citation>Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007 Nov;26(11):1871-5. Epub 2007 Feb 28.</citation>
    <PMID>17332971</PMID>
  </results_reference>
  <results_reference>
    <citation>Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med. 1999 Mar 2;130(5):422-6.</citation>
    <PMID>10068416</PMID>
  </results_reference>
  <results_reference>
    <citation>Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005 Oct;10(5):504-10.</citation>
    <PMID>16221103</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Yang Y, Zhao J, Li M, Tian X, Zeng X. The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. Sci Rep. 2016 Dec 7;6:38687. doi: 10.1038/srep38687.</citation>
    <PMID>27924855</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Xinping Tian</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

